Note : Les descriptions sont présentées dans la langue officielle dans laquelle elles ont été soumises.
CA 02926726 2016-04-06
WO 2015/066443 PCT/US2014/063372
CONVENIENT PREPARATION OF N-SUBSTITUTED MORPHINAN-6-OLS FROM
MORPHINAN-6-ONES
Field of the Invention
[0001] Disclosed herein are methods of preparing N-alkyl morphinan-6-
ols
from morphinan-6-ones, in a one-pot procedure.
Background of the Invention
[0002] N-substituted nnorphinan-6-ols such as naltrexol, naloxol, and
nalbuphine, are important narcotic pharmaceuticals. The current processes for
preparing such compounds either 1) comprise several separate steps in which
the
introduction of the nitrogen substituent is performed before or after the
reduction of the
6-keto group to an alcohol, or 2) conduct a one-pot procedure but use a
transition metal
catalyst and hydrogen gas. The first route is inefficient, while the second
route is
susceptible to catalyst poisoning, does not afford acceptable
stereoselectivity, and/or
requires the use of expensive, chiral catalysts. Therefore, there is a need
for a cost
effective, one-pot process that affords high diastereomeric purity.
Summary of the Invention
[0003] Disclosed herein are methods of preparing compounds of formula
(I),
R2
R3
0
R25
711
R14 NI--)C1"--Ri0
(I)
the methods comprising, contacting compounds of formula (II)
1
CA 02926726 2016-04-06
WO 2015/066443 PCT/US2014/063372
R2
R3
0
R14 NH
0 (II)
with a boron based reducing agent, and
a carbonyl compound of the formula:
0
rµio
an acylating agent, or
an alkylating agent, wherein
the contacting is optionally conducted in a solvent; and wherein
at each occurrence, = is independently a single or double bond;
L is absent, -C(0)- or ¨SO2-;
n is 0 or 1;
R1 is H, C1-C6 alkyl, C1-C6 alkoxy, OH, or ¨0-Pro;
R2 is H, C1-C6 alkyl, C1-C6 alkoxy, OH, or ¨0-Pro;
R3 is H, C1-C6 alkyl, C1-C6 alkoxy, OH, or ¨0-Pro, wherein
Pro, at each occurrence, is independently a hydroxyl protecting group;
R10 is 01-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, 03-C8 cycloalkyl, -01-C6
alkyl-aryl,
-C2-C6 alkenyl-aryl, -C2-C6 alkynyl-aryl, -C1-C6 alkyl-heteroaryl, -C2-C6
alkenyl-
heteroaryl, -C2-C6 alkynyl-heteroaryl, -Ci-C6 alkyl- heterocycloalkyl, -C2-C6
alkenyl-
heterocycloalkyl, -C2-C6 alkynyl-heterocycloalkyl, -C1-C6 alkyl-C3-C8
cycloalkyl, -C2-C6
alkenyl-C3-C8 cycloalkyl, -C2-C6 alkynyl- C3-C8 cycloalkyl, or C1-C6 alkoxy C1-
C6 alkyl;
R11 is H, absent, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl,
C6 alkyl-aryl, -C2-C6 alkenyl-aryl, -C2-C6 alkynyl-aryl, alkyl-heteroaryl, -
C2-C6
alkenyl-heteroaryl, -C2-C6 alkynyl-heteroaryl, -C1-C6 alkyl- heterocycloalkyl,
-C2-C6
alkenyl- heterocycloalkyl, -C2-C6 alkynyl-heterocycloalkyl, -C1-C6 alkyl-C3-C8
cycloalkyl,
-C2-C6 alkenyl-C3-C8 cycloalkyl, -C2-C6 alkynyl- C3-G8 cycloalkyl, or C1-C6
alkoxy Ci-C6
alkyl;
2
CA 02926726 2016-04-06
WO 2015/066443 PCMJS2014/063372
wherein each aryl group is unsubstituted or substituted at one or more
substitutable
positions with a group that is independently C1-C6 alkyl, C2-C6 alkenyl, C2-C6
alkynyl,
Ci-C6 alkoxy, OPro, halo, C1-C6 haloalkyl or Ci-C6 haloalkoxy; and
wherein each heteroaryl group is unsubstituted or substituted at one or more
substitutable positions with a group that is independently C1-C6 alkyl, C2-C6
alkenyl, 02-
C6 alkynyl, 01-C6 alkoxy, OPro, halo, C1-06 haloalkyl or Ci-C6 haloalkoxy; and
wherein each heterocycloalkyl group is unsubstituted or substituted at one or
more
substitutable positions with a group that is independently C1-C6 alkyl, C2-C6
alkenyl, 02-
C6 alkynyl, 01-C6 alkoxy, OPro, halo, C1-06 haloalkyl or C1-C6 haloalkoxy;
R14 is H or OH; and
R25 is 0 if --- is a double bond, or R25 is OH, if --- is a single bond;
provided that when the compound of formula (II) is contacted with the carbonyl
compound, n is 1 and L is absent;
provided that when the compound of formula (II) is contacted with the
acylating agent, L
is ¨C(0)- or -SO2-; and when the acylating agent is an acid anhydride, then n
is 0; and
provided that when the compound of formula (II) is contacted with the
alkylating agent, L
is absent.
[0004] Also disclosed herein are one-pot methods wherein the NH group
of formula (II) is treated with a carbonyl compound, such as an aldehyde or
ketone, and
a reducing agent (preferably a boron based reducing agent), and wherein the 6-
keto
group is reduced to a 6-hydroxy group.
[0005] Furthermore, disclosed herein are one-pot methods wherein the
NH
group of formula (II) is contacted treated with an alkylating agent and a
base, thereby
generating an N-alkyl group, and wherein the 6-keto group is reduced to a 6-
hydroxy
group by the addition of a reducing agent. Alternatively, the reduction of the
6-keto
group to the 6-hydroxy group may be conducted before NH group is alkylated.
[0006] One-pot methods wherein the NH group of formula (II) is
acylated
with an acylating agent and a base, thereby generating an N-acyl group, and
wherein
the 6-keto group is reduced to a 6-hydroxy group by the addition of a reducing
agent are
3
CA 02926726 2016-04-06
WO 2015/066443 PCMJS2014/063372
also disclosed herein. Alternatively, the reduction of the 6-keto group to the
6-hydroxy
group may be conducted before NH group is alkylated.
Detailed Description
[0007] In general, the morphinans detailed herein include any
compound
comprising a morphinan structure as diagrammed below. For the purposes of
illustration, the ring atoms of the core morphinan structure are numbered as
diagrammed below, wherein R is hydrogen, hydrocarbyl or substituted
hydrocarbyl:
2
3 40 1
4 11
0 12 1
16
*13 9
5 14 NR
17
6 IP 8
7
[0008] Morphinan compounds have asymmetric centers. In particular,
the
core morphinan compound may have at least four chiral carbons (designated by
asterisks); namely, C-5, C-13, C-14, and C-9. Thus, each chiral center may
have an R
or an S configuration. The configuration of C-5, C-9, C-13, and C-14,
respectively, may
be RRRR, RRRS, RRSR, RSRR, SRRR, RRSS, RSSR, SSRR, SRRS, SRSR, RSRS,
RSSS, SRSS, SSRS, SSSR, or SSSS, provided that the C-15 and C-16 atoms are
both
on the alpha face of the molecule or are both on the beta face of the
molecule. Thus,
the compounds disclosed herein may have a (-) or a (+) orientation with
respect to the
rotation of polarized light.
[0009] For the sake of clarity, it should be noted that when n is 0,
the
compound of formula (I) becomes:
4
CA 02926726 2016-04-06
WO 2015/066443
PCMJS2014/063372
R2
R3
0
R14 NsvR10
R25-'
[0010] As
described above, disclosed herein are methods of converting
compounds of formula (II) into compounds of formula (I) via a one-pot process.
In the
disclosed one-pot processes, preferably, two transformations occur. One is the
reduction of the 6-keto group to the 6-hydroxy group, and the other is
replacing the
hydrogen on the NH group with one of the groups described herein.
[0011] When the
6-keto group of formula (II) is reduced, a mixture of 6-
alpha-hydroxyl and 6-beta-hydroxy epimers are formed. Without wishing to be
bound to
a particular theory, it is believe that the steric size of the reducing agent
favors the
formation of the 6-alpha-hydroxy epimer. The epimeric ratio of the 6-alpha-
hydroxy
morphinan epimer to the 6-beta-hydroxy morphinan epimers is generally greater
than or
equal to 9:1. More preferably, the epimeric ratio may be greater than or equal
to 95:5.
Still more preferably, the epimeric ratio may be greater than or equal to
96:4. More
preferably still, the ratio may be greater than or equal to 97:3. Still more
preferably, the
epimeric ratio may be greater than or equal to 98:2. Most preferably, the
epimeric ratio
may be greater than or equal to 99:1.
[0012] If
desired, the methods disclosed herein may be conducted in a
solvent or a mixture of solvents. In general, the solvent may be an aprotic
polar solvent.
Non-limiting examples of suitable aprotic solvents include acetonitrile, N,N-
dimethylformamide (DMF), dimethyl sulfoxide (DMSO), N,N-dimethylpropanamide
(or
dimethylpropionamide; DMP), 1,3-dimethy1-3,4,5,6-tetrahydro-2(1H)-pyrimidinone
(DMPU), 1,3-dimethy1-2-imidazolidinone (DMI), 1,2-dimethoxyethane (DME),
dimethoxymethane, bis(2-methoxyethyl)ether, N,N-dimethylacetamide (DMA), N-
methy1-2-pyrrolidinone (NMP), 1,4-dioxane, ethyl formate, formamide,
hexachloroacetone, hexamethylphosphoramide, methyl acetate, N-methylacetamide,
N-methylformamide, methylene chloride, methoxyethane, morpholine,
nitrobenzene,
CA 02926726 2016-04-06
WO 2015/066443 PCMJS2014/063372
nitromethane, propionitrile, pyridine, sulfolane, tetramethylurea,
tetrahydrofuran (THF),
2-methyl tetrahydrofuran, tetrahydropyran, trichloromethane, and combinations
thereof.
In certain embodiments, the solvent may be tetrahydrofuran (THF),
dichloromethane,
dimethylformamide (DMF), dimethylacetamide (DMA), N-methylpyrrolidine (NMP) or
combinations thereof. In exemplary embodiments, the methods may be conducted
in
DMF, DMA, NMP, or combinations thereof.
[0013] In general, the weight to weight ratio of the solvent to the
compound of formula (II) may range from about 0.5:1 to about 100:1. In various
embodiments, the weight ratio of the solvent to the compound of formula (II)
may range
from 0.5:1 to about 5:1, from about 5:1 to about 25:1, or from about 25:1 to
about 100:1.
In exemplary embodiments, the weight ratio of the solvent to the compound of
formula
(I) may range from about 0.5:1 to about 10:1.
[0014] The methods disclosed herein utilize large, sterically
hindered
reducing agents. Preferably, the reducing agent is a hydride reducing agent.
Still more
preferably, it is a boron based reducing agent. One preferred boron reducing
agent
may be MBHnR4-n, wherein M is Li, Na, or K; n is 1 or 2; and each R is
independently ¨
02C-(C1-05 alkyl), with M being Na or K more preferred than Li, and Na being
preferred
over K. Additionally, in a preferred aspect, the "-02C-(C1-05 alkyl)" group
may be "-
02CCH3." A preferred reducing agent, that is capable of reducing the 6-keto to
a
hydroxyl and the imine formed when the NH group reacts with an aldehyde or
ketone,
may be sodium triacetoxyborohydride, which has the following formula:
NaBH(02CCH3)3.
[0015] When the sterically hindered, boron reducing agent is added to
the
reaction mixture, it may be added as a solid, or it may be dissolved in a
solvent or
combination of solvents. Preferably, it is dissolved in a solvent or mixture
of solvents
that are the same as those used in the reaction mixture.
[0016] The amount of reducing agent used can and will vary depending
upon the number of transformations the reducing agent conducts. In general,
from
about 1 to about 10 equivalents of the reducing agent may be used. It is
preferred to
use the least amount of reducing agent necessary to conduct the desired
6
CA 02926726 2016-04-06
WO 2015/066443 PCMJS2014/063372
transformation(s). In certain embodiments, the amount of reducing agent may
range
from about 1 to about 2 equivalents, from about 2 to about 4 equivalents, or
from about
4 to about 10 equivalents. In exemplary embodiments, from about 2 to about 3.5
equivalents of the reducing agent may be used.
[0017] The reaction temperatures and times may vary, depending on the
nature of the transformation or transformations that are being conducted.
Typically, the
reactions are conducted at temperatures from about 0 C up to the reflux
temperature of
the solvent. In some embodiments, the temperature of the may range from about
0 00
to about 100 C. In other embodiments, the temperature of the may range from
about 0
C to about 30 C, or more preferably at about 20 C. Reaction times typically
range
from about 10 minutes up to about 48 hours. For example, the reaction time may
range
from about 3 hours to about 8 hours, or from about 8 hours to about 20 hours.
The
ability to determine more specific temperatures and times is within the
abilities of one
having ordinary skill in the art.
[0018] When conducting the methods described herein, various orders
of
mixing the reagents may be used, and the order may depend on the specific
transformation(s) that occur.
[0019] In one aspect, the compounds of formula (II) are contacted
with a
reducing agent (as described above) and an aldehyde or ketone of the formula
0
A
[0020] More preferably, R10 is 01-06 alkyl, 02-C6 alkenyl, 02-C6
alkynyl, 03-
C8 cycloalkyl, -Ci-C6 alkyl-aryl, -C2-C6 alkenyl-aryl, -C2-C6 alkynyl-aryl, -
C1-06 alkyl-
heteroaryl, -C2-C6 alkenyl-heteroaryl, -02-06 alkynyl-heteroaryl, -01-C6 alkyl-
heterocycloalkyl, -C2-C6 alkenyl- heterocycloalkyl, -C2-C6 alkynyl-
heterocycloalkyl, -Cr
C6 alkyl-C3-C8 cycloalkyl, -C2-C6 alkenyl-C3-08 cycloalkyl, -C2-C6 alkynyl- 03-
C8
cycloalkyl, or Ci-C6 alkoxy C1-C6 alkyl; and
R11 is H, 01-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, -Ci-C6
alkyl-
aryl, -C2-06 alkenyl-aryl, -C2-C6 alkynyl-aryl, -C1-06 alkyl-heteroaryl, -C2-
C6 alkenyl-
heteroaryl, -02-C6 alkynyl-heteroaryl, -C1-06 alkyl- heterocycloalkyl, -02-C6
alkenyl-
7
CA 02926726 2016-04-06
WO 2015/066443 PCMJS2014/063372
heterocycloalkyl, -C2-C6 alkynyl-heterocycloalkyl, alkyl-C3-C8 cycloalkyl, -
C2-C6
alkenyl-C3-C8 cycloalkyl, -C2-C6 alkynyl- C3-C8 cycloalkyl, or C1-C6 alkoxy Ci-
C6 alkyl;
wherein each aryl group is independently phenyl or naphthyl, and each aryl is
unsubstituted or substituted at one or more substitutable positions with a
group that is
independently C1-C6 alkyl, C2-C6 alkenyl, 02-C6 alkynyl, C1-06 alkoxy, OPro,
halo, C1-C6
haloalkyl or Ci-C6 haloalkoxy;
wherein each heteroaryl group is independently pyrrolyl, imidazolyl,
triazolyl, pyridyl,
pyridazinyl, pyrimidyl, pyrazinyl, triazinyl, indolyl, quinolinyl, furanyl,
benzofuranyl,
thienyl, or benzothienyl, and each heteroaryl is unsubstituted or substituted
at one or
more substitutable positions with a group that is independently C1-C6 alkyl,
C2-C6
alkenyl, C2-G6 alkynyl, C1-C6 alkoxy, OPro, halo, C1-C6 haloalkyl or C1-C6
haloalkoxy;
and
wherein each heterocycloalkyl group is pyrrolidinyl, imidazolidinyl,
oxazolidinyl,
thiazolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, or morpholinyl,
and each
heterocycloalkyl is unsubstituted or substituted at one or more substitutable
positions
with a group that is independently C1-C6 alkyl, C2-G6 alkenyl, C2-G6 alkynyl,
C1-C6
alkoxy, OPro, halo, C1-C6 haloalkyl or C1-C6 haloalkoxy.
[0021] Still more preferably, R10 is C1-C6 alkyl, -C1-C6 alkyl-
phenyl, C3-C6
cycloalkyl, alkyl-C3-C6 cycloalkyl, or allyl; and R11 is H, C1-C6 alkyl, -
C1-C6 alkyl-
phenyl, C3-C6 cycloalkyl, -C1-C6 alkyl-C3-C6 cycloalkyl, or allyl;
wherein each phenyl group is unsubstituted or substituted at one or more
substitutable
positions with a group that is independently C1-C6 alkyl, C2-C6 alkenyl, C2-C6
alkynyl,
Ci-C4 alkoxy, OPro, halo, C1-C4 haloalkyl or Ci-C4 haloalkoxy.
[0022] In one preferred embodiment, R11 is H.
[0023] In one preferred embodiment, R1 is H and R2 is H and R3 is OH,
methoxy or OPro, wherein Pro is as defined herein.
[0024] In one embodiment, R25 is OH and = is a single bond.
[0025] In an alternate embodiment, R25 is 0 and --- is a double bond.
[0026] When conducting the reductive amination reaction, typically
from
about 1 to about 10 equivalents of aldehyde or ketone may be used. In various
8
CA 02926726 2016-04-06
W02015/066443 PCMJS2014/063372
embodiments, the amount of aldehyde or ketone used may range from about 1 to
about
2 equivalents, from about 2 to about 4 equivalents, or from about 4 to about
10
equivalents. In one embodiment, about 1.0 to about 1.2 equivalents of aldehyde
or
ketone may be used.
[0027] If desired, an acid may be added to the reaction mixture.
Acceptable acids include the mineral acids, such as HCI or H2SO4, or organic
acids,
such as formic acid or acetic acid. If desired, a combination of two or more
acids may
be used. A preferred acid is acetic acid.
[0028] In various embodiments, the compound of formula (II) may be
noroxycodone, norhydromorphone, norhydrocodone, normorphinone, or
norcodeinone.
In one embodiment, the compound of formula (II) may be noroxymorphone, which
has
the following structure:
HO
OH NH
0
[0029] In this iteration, compounds of formula (I) that can be made
using
the methods described herein include, but are not limited to nalbuphine, 6a-
naltrexol,
nalbuphone, and naltrexone, which have the following structures:
HO HO
OH Njj7 OH N.N.../A
HO
HO's.
Nalbuphine 6a-Naltrexol
9
CA 02926726 2016-04-06
WO 2015/066443 PCMJS2014/063372
HO HO
0
OH N=ji::7
OH N/A
0 0
Nalbu phone Naltrexone
[0030] In an embodiment, the compound of formula (II) is
noroxymorphone, and the compound of formula (I) is nalbuphine.
[0031] In another embodiment, the compound of formula (II) is
noroxymorphone and the compound of formula (I) is 6a-naltrexol.
[0032] In yet another embodiment, the compound of formula (II) is
noroxymorphone and the compound of formula (I) is naltrexone.
[0033] In still another embodiment, the compound of formula (II) is
noroxymorphone and the compound of formula (I) is nalbuphone.
[0034] In an alternative aspect, the compounds of formula (II) are
contacted with a reducing agent (as described above) and an alkylating agent.
Examples of alkylating agents include those of the formula
Rur\--
[0035] More preferably, R10 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6
alkynyl, C3-
C8 cycloalkyl, -C1-C6 alkyl-aryl, -C2-C6 alkenyl-aryl, -C2-C6 alkynyl-aryl, -
C1-C6 alkyl-
heteroaryl, -C2-C6 alkenyl-heteroaryl, -C2-C6 alkynyl-heteroaryl, -Ci-C6 alkyl-
heterocycloalkyl, -C2-06 alkenyl-heterocycloalkyl, -C2-C6 alkynyl-
heterocycloalkyl,
alkyl-C3-C8 cycloalkyl, -C2-C6 alkenyl-C3-C8 cycloalkyl, -C2-C6 alkynyl- C3-C8
cycloalkyl,
or C1-C6 alkoxy C1-C6 alkyl; and
R11 is H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, -Ci-C6
alkyl-
aryl, -C2-C6 alkenyl-aryl, -C2-C6 alkynyl-aryl, -Ci-C6 alkyl-heteroaryl, -C2-
C6 alkenyl-
heteroaryl, -C2-C6 alkynyl-heteroaryl, -C1-C6 alkyl- heterocycloalkyl, -C2-C6
alkenyl-
CA 02926726 2016-04-06
WO 2015/066443 PCMJS2014/063372
heterocycloalkyl, -C2-C6 alkynyl-heterocycloalkyl, alkyl-C3-C8 cycloalkyl, -
C2-C6
alkenyl-C3-C8 cycloalkyl, -C2-C6 alkynyl- C3-C8 cycloalkyl, or C1-C6 alkoxy Ci-
C6 alkyl;
wherein each aryl group is independently phenyl or naphthyl, and each aryl is
unsubstituted or substituted at one or more substitutable positions with a
group that is
independently C1-C6 alkyl, C2-C6 alkenyl, 02-C6 alkynyl, C1-06 alkoxy, OPro,
halo, C1-C6
haloalkyl or Ci-C6 haloalkoxy;
wherein each heteroaryl group is independently pyrrolyl, imidazolyl,
triazolyl, pyridyl,
pyridazinyl, pyrimidyl, pyrazinyl, triazinyl, indolyl, quinolinyl, furanyl,
benzofuranyl,
thienyl, or benzothienyl, and each heteroaryl is unsubstituted or substituted
at one or
more substitutable positions with a group that is independently C1-C6 alkyl,
C2-C6
alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, OPro, halo, C1-C6 haloalkyl or C1-C6
haloalkoxy;
wherein each heterocycloalkyl group is pyrrolidinyl, imidazolidinyl,
oxazolidinyl,
thiazolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, or morpholinyl,
and each
heterocycloalkyl is unsubstituted or substituted at one or more substitutable
positions
with a group that is independently C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl,
Ci-C6
alkoxy, OPro, halo, C1-C6 haloalkyl or C1-C6 haloalkoxy; and
X is a leaving group.
[0036] Still more preferably, R10 is C1-C6 alkyl, -C1-C6 alkyl-
phenyl, C3-C6
cycloalkyl, alkyl-C3-C6 cycloalkyl, or allyl; and R11 is H, C1-C6 alkyl, -
C1-C6 alkyl-
phenyl, C3-C6 cycloalkyl, -C1-C6 alkyl-C3-C6 cycloalkyl, or allyl; wherein
each phenyl
group is unsubstituted or substituted at one or more substitutable positions
with a group
that is independently C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C4 alkoxy,
OPro, halo,
C1-C4 haloalkyl or Ci-C4 haloalkoxy.
[0037] In one preferred embodiment, R11 is H.
[0038] In one preferred embodiment, R1 is H and R2 is H and R3 is OH,
methoxy or OPro, wherein the Pro group was previously defined.
[0039] In another preferred embodiment, X is halo, -0S02CF3, -
0S02CF13,
tosyl, brosyl, or nosyl.
[0040] In one embodiment, n is 0.
[0041] In another embodiment, n is 1.
11
CA 02926726 2016-04-06
WO 2015/066443 PCMJS2014/063372
[0042] In one embodiment, the methods disclosed herein are conducted
in
a solvent or a mixture of solvents. In general, the solvent may be an aprotic
polar
solvent. Non-limiting examples of suitable aprotic solvents include acetone,
acetonitrile,
diethoxymethane, N,N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), N,N-
dimethylpropanamide (or dimethylpropionamide; DMP), 1,3-dimethy1-3,4,5,6-
tetrahydro-
2(1H)-pyrimidinone (DMPU), 1,3-dimethy1-2-imidazolidinone (DMI), 1,2-
dimethoxyethane (DME), dimethoxymethane, bis(2-methoxyethyl)ether, N,N-
dimethylacetamide (DMA), N-methyl-2-pyrrolidinone (NMP), 1,4-dioxane, ethyl
formate,
formamide, hexachloroacetone, hexamethylphosphoramide, methyl acetate, N-
methylacetamide, N-methylformamide, methylene chloride, methoxyethane,
morpholine, nitrobenzene, nitromethane, propionitrile, pyridine, sulfolane,
tetramethylurea, tetrahydrofuran (THF), 2-methyl tetrahydrofuran,
tetrahydropyran,
trichloromethane, and combinations thereof. In certain embodiments, the
solvent may
be tetrahydrofuran (THF), dichloromethane, dimethylformamide (DMF),
dimethylacetamide (DMA), N-methylpyrrolidine (NMP) or combinations thereof. In
exemplary embodiments, the methods may be conducted in DMF, DMA, NMP, or
combinations thereof.
[0043] In general, the weight to weight ratio of the solvent to the
compound of formula (II) may range from about 0.5:1 to about 100:1. In various
embodiments, the weight ratio of the solvent to the compound of formula (II)
may range
from 0.5:1 to about 5:1, from about 5:1 to about 25:1, or from about 25:1 to
about 100:1.
In exemplary embodiments, the weight ratio of the solvent to the compound of
formula
(1) may range from about 0.5:1 to about 10:1.
[0044] When conducting the alkylation reaction, the solvent may
further
comprise a base. Examples of suitable bases include inorganic bases (such as
carbonates, bicarbonates and hydroxides of the group 1 and group 2 elements of
the
periodic table) and amine containing bases. Examples of amine containing bases
include triethylamine, diisopropylethylamine, lutidine, pyridine, or 2,6-di-
tert-butyl
pyridine or combinations thereof. Preferred amine bases comprise
triethylamine,
diisopropylethylamine and combinations thereof.
12
CA 02926726 2016-04-06
WO 2015/066443 PCMJS2014/063372
[0045] In one embodiment, R25 is OH and ¨ is a single bond.
[0046] When conducting the alkylation reaction, typically from about 1 to
about 10 equivalents of alkylating agent may be used. In various embodiments,
the
amount of alkylating agent used may range from about 1 to about 2 equivalents,
from
about 2 to about 4 equivalents, or from about 4 to about 10 equivalents. In
one
embodiment, about 1.0 to about 1.2 equivalents of alkylating agent may be
used.
[0047] In an embodiment, the compound of formula (II) is
noroxymorphone, and the compound of formula (I) is nalbuphine.
[0048] In another embodiment, the compound of formula (II) is
noroxymorphone and the compound of formula (I) is 6a-naltrexol.
[0049] In another aspect, compounds of formula (II) are contacted with a
reducing agent (as described above) and an acylating agent. Examples of
acylating
agents include those the formula
0 0
J.L
1-µ10 IA11 or Rio 0 Rio
wherein Z is ¨C(0)-G or ¨S02-G, and wherein G is halo.
[0050] More preferably, Rio is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl,
C3-
C8 cycloalkyl, -C1-C6 alkyl-aryl, -C2-C6 alkenyl-aryl, -C2-C6 alkynyl-aryl, -
C1-C6 alkyl-
heteroaryl, -C2-C6 alkenyl-heteroaryl, -C2-C6 alkynyl-heteroaryl, -C1-C6
alkyl-
heterocycloal -C2-C6 alkenyl-heterocycloalkyl, -C2-C6 alkynyl-
heterocycloalkyl, -Ci-C6
alkyl-C3-C8 cycloalkyl, -C2-C6 alkenyl-C3-C8 cycloalkyl, -C2-C6 alkynyl- C3-C8
cycloalkyl,
or C1-C6 alkoxy C1-C6 alkyl; and
R11 is H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, -Ci-C6
alkyl-
aryl, -C2-C6 alkenyl-aryl, -C2-C6 alkynyl-aryl, -Ci-C6 alkyl-heteroaryl, -C2-
C6 alkenyl-
heteroaryl, -C2-C6 alkynyl-heteroaryl, -C1-C6 alkyl- heterocycloalkyl, -C2-C6
alkenyl-
heterocycloalkyl, -C2-06 alkynyl-heterocycloalkyl, -C1-C6 alkyl-C3-C8
cycloalkyl, -C2-C6
alkenyl-C3-C8 cycloalkyl, -C2-06 alkynyl- C3-08 cycloalkyl, or C1-C6 alkoxy C1-
C6 alkyl;
wherein each aryl group is independently phenyl or naphthyl, and each aryl is
unsubstituted or substituted at one or more substitutable positions with a
group that is
13
CA 02926726 2016-04-06
WO 2015/066443 PCMJS2014/063372
independently C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, OPro,
halo, C1-C6
haloalkyl or Ci-C6 haloalkoxy;
wherein each heteroaryl group is independently pyrrolyl, imidazolyl,
triazolyl, pyridyl,
pyridazinyl, pyrimidyl, pyrazinyl, triazinyl, indolyl, quinolinyl, furanyl,
benzofuranyl,
thienyl, or benzothienyl, and each heteroaryl is unsubstituted or substituted
at one or
more substitutable positions with a group that is independently C1-C6 alkyl,
C2-C6
alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, OPro, halo, C1-C6 haloalkyl or C1-C6
haloalkoxy;
and
wherein each heterocycloalkyl group is pyrrolidinyl, imidazolidinyl,
oxazolidinyl,
thiazolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, or morpholinyl,
and each
heterocycloalkyl is unsubstituted or substituted at one or more substitutable
positions
with a group that is independently C1-06 alkyl, C2-C6 alkenyl, C2-06 alkynyl,
Ci-C6
alkoxy, OPro, halo, C1-C6 haloalkyl or C1-06 haloalkoxy.
[0051] Still more preferably, R10 is Ci-C6 alkyl, -Ci-C6 alkyl-
phenyl, C3-C6
cycloalkyl, alkyl-C3-C6 cycloalkyl, or allyl; and R11 is H, C1-C6 alkyl, -
Ci-C6 alkyl-
phenyl, C3-C6 cycloalkyl, alkyl-C3-C6 cycloalkyl, or allyl;
wherein each phenyl group is unsubstituted or substituted at one or more
substitutable
positions with a group that is independently C1-C6 alkyl, C2-C6 alkenyl, C2-C6
alkynyl,
Ci-C4 alkoxy, OPro, halo, C1-C4 haloalkyl or Ci-C4 haloalkoxy.
[0052] In one preferred embodiment, R11 is H.
[0053] In one embodiment, G is chloro.
[0054] In another embodiment, Z is ¨C(0)-G and G is chloro.
[0055] In still another embodiment, Z is ¨S02-G, and G is chloro.
[0056] In a preferred embodiment, R1 is H and R2 is H and R3 is OH,
methoxy or OPro, wherein the Pro group was previously defined.
[0057] Still more preferably, R1 is H and R2 is H and R3 is OH,
methoxy or
OPro and G is chloro.
[0058] In one embodiment, the methods disclosed herein are conducted
in
a solvent or a mixture of solvents. In general, the solvent may be an aprotic
polar
solvent. Non-limiting examples of suitable aprotic solvents include acetone,
acetonitrile,
14
CA 02926726 2016-04-06
WO 2015/066443 PCMJS2014/063372
diethoxymethane, N,N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), N,N-
dimethylpropanamide (or dimethylpropionamide; DMP), 1,3-dimethy1-3,4,5,6-
tetrahydro-
2(1H)-pyrimidinone (DMPU), 1,3-dimethy1-2-imidazolidinone (DMI), 1,2-
dimethoxyethane (DME), dimethoxymethane, bis(2-methoxyethyl)ether, N,N-
dimethylacetamide (DMA), N-methyl-2-pyrrolidinone (NMP), 1,4-dioxane, ethyl
formate,
formamide, hexachloroacetone, hexannethylphosphoramide, methyl acetate, N-
methylacetamide, N-methylformamide, methylene chloride, methoxyethane,
morpholine, nitrobenzene, nitromethane, propionitrile, pyridine, sulfolane,
tetramethylurea, tetrahydrofuran (THF), 2-methyl tetrahydrofuran,
tetrahydropyran,
trichloromethane, and combinations thereof. In certain embodiments, the
solvent may
be tetrahydrofuran (THF), dichloromethane, dimethylformamide (DMF),
dimethylacetamide (DMA), N-methylpyrrolidine (NMP) or combinations thereof. In
exemplary embodiments, the methods may be conducted in DMF, DMA, NMP, or
combinations thereof.
[0059] In general, the weight to weight ratio of the solvent to the
compound of formula (II) may range from about 0.5:1 to about 100:1. In various
embodiments, the weight ratio of the solvent to the compound of formula (II)
may range
from 0.5:1 to about 5:1, from about 5:1 to about 25:1, or from about 25:1 to
about 100:1.
In exemplary embodiments, the weight ratio of the solvent to the compound of
formula
(1) may range from about 0.5:1 to about 10:1.
[0060] When acylating the compound of formula (II), the solvent may
further comprise a base. Examples of suitable bases include inorganic bases
and
amine containing bases. Examples of amine containing bases include
triethylamine,
diisopropylethylamine, lutidine, pyridine, or 2,6-di-tert-butyl pyridine or
combinations
thereof. Preferred amine bases comprise triethylamine, diisopropylethylamine
and
combinations thereof.
[0061] In a preferred embodiment, R25 is OH and = is a single bond.
[0062] When conducting the acylation reaction, typically from about 1
to
about 10 equivalents of acylating agent may be used. In various embodiments,
the
amount of acylating agent used may range from about 1 to about 2 equivalents,
from
CA 02926726 2016-04-06
WO 2015/066443 PCMJS2014/063372
about 2 to about 4 equivalents, or from about 4 to about 10 equivalents. In
one
embodiment, about 1.0 to about 1.2 equivalents of acylating agent may be used.
[0063] In a preferred embodiment, according to anyone of the
preceding
aspects and/or embodiments, R14 is OH.
[0064] In an alternative preferred embodiment, according to anyone of
the
preceding aspects and/or embodiments, R14 is H.
[0065] In a further preferred embodiments, according to anyone of the
preceding aspects and/or embodiments, R1 is H, R2 is H and R3 is OH, methoxy,
or
OPro.
[0066] If desired, the olefin between carbons 7 and 8 may be reduced
using methods known in the art, such as Pd/C with hydrogen gas.
[0067] The reactions described above in the various aspects are
typically
conducted under an inert atmosphere. However, if desired, a standard
atmosphere
(i.e., not inert) may be used.
[0068] After the completion of the reaction(s), the resulting product
may be
isolated using methods known in the art, such as distillation, chromatography
or the
separation of diastereomeric salts.
[0069] The molar yields of the above reactions are typically better
than
about 80%, or 85%, or 90%.
[0070] After the completion of the above reactions, if desired, the
resulting
compound of formula (I) may be converted into a pharmaceutically acceptable
salt. The
term "pharmaceutically-acceptable salts" are salts commonly used to form
alkali metal
salts and to form addition salts of free acids or free bases. The nature of
the salt may
vary, provided that it is pharmaceutically acceptable. Suitable
pharmaceutically
acceptable acid addition salts of compounds of formula (I) may be prepared
from an
inorganic acid or from an organic acid. Examples of such inorganic acids are
hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric and
phosphoric acid.
Appropriate organic acids may be selected from aliphatic, cycloaliphatic,
aromatic,
araliphatic, heterocyclic, carboxylic and sulfonic classes of organic acids,
examples of
which are formic, acetic, propionic, succinic, glycolic, gluconic, lactic,
malic, tartaric,
16
CA 02926726 2016-04-06
WO 2015/066443 PCMJS2014/063372
citric, ascorbic, glucuronic, nnaleic, funnaric, pyruvic, aspartic, glutannic,
benzoic,
anthranilic, mesylic, 4-hydroxybenzoic, phenylacetic, nnandelic, ennbonic
(pannoic),
nnethanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic, 2-
hydroxyethanesulfonic, toluenesulfonic, sulfanilic, cyclohexylaminosulfonic,
stearic,
algenic, hydroxybutyric, salicylic, galactaric and galacturonic acid. Suitable
pharmaceutically-acceptable base addition salts include metallic salts made
from
aluminum, calcium, lithium, magnesium, potassium, sodium and zinc or organic
salts
made from N, N'-dibenzylethylenediamine, chloroprocaine, choline,
diethanolamine,
ethylenediamine, meglumine (N-methylglucamine), and procaine. All of these
salts may
be prepared by conventional means from the corresponding compound by reacting,
for
example, the appropriate acid or base with the compound of formula (I).
Definitions
[0071] As used herein, "about," when referring to a numerical value,
refers
to that numerical value, plus or minus 10%. Thus, "about 80" should be
understood to
encompass the range of 72 to 88.
[0072] The terms "aryl," as used herein alone or as part of another
group
denote optionally substituted homocyclic aromatic groups, preferably
monocyclic or
bicyclic groups containing from 6 to 10 carbons in the ring portion, such as
phenyl,
biphenyl, naphthyl, phenanthracenyl, or anthracenyl. Preferred aryl groups
include
phenyl, and naphthyl, with phenyl being most preferred.
[0073] The term "heteroaryl" as used herein alone or as part of
another
group denotes aromatic groups having at least one heteroatom in at least one
ring, and
preferably 5 or 6 atoms in each ring. The heteroaromatic group preferably has
1 or 2
oxygen atoms and/or 1 to 4 nitrogen atoms in the ring, and is bonded to the
remainder
of the molecule through a carbon. Exemplary groups include furanyl,
benzofuranyl,
oxazolyl, isoxazolyl, oxadiazolyl, benzoxazolyl, benzoxadiazolyl, pyrrolyl,
pyrazolyl,
imidazolyl, triazolyl, tetrazolyl, pyridyl, pyrim idyl, pyrazinyl,
pyridazinyl, triazinyl, indolyl,
thienyl, benzothienyl, isoindolyl, indolizinyl, benzimidazolyl, indazolyl,
benzotriazolyl,
tetrazolopyridazinyl, carbazolyl, purinyl, quinolinyl, isoquinolinyl, and
imidazopyridyl.
17
CA 02926726 2016-04-06
WO 2015/066443 PCMJS2014/063372
[0074] As used herein, "heterocycloalkyl" as used herein alone or as
part
of another group denotes a saturated or partially saturated three to 10
membered ring
system, wherein the saturated or partially saturated ring(s) are optionally
fused or
bonded to other aryl groups and/or heteroaryl groups. Examples of
heterocycloalkyl
groups include pyrrolidinyl, imidazolidinyl, oxazolidinyl, thiazolidinyl,
tetrahydrofuranyl,
piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, indolinyl, and
tetrahydroisoquinolinyl.
[0075] The term "hydrocarbyl" as used herein refers to organic
compounds
or radicals consisting exclusively of the elements carbon and hydrogen. These
moieties
include alkyl, alkenyl, alkynyl, and aryl moieties. These moieties also
include alkyl,
alkenyl, alkynyl, and aryl moieties substituted with other aliphatic or cyclic
hydrocarbon
groups, such as alkaryl, alkenaryl and alkynaryl. Unless otherwise indicated,
these
moieties preferably comprise 1 to 20 carbon atoms.
[0076] As used herein, "Pro" denotes a group capable of protecting an
oxygen atom (and hence, forming a protected hydroxy), wherein the protecting
group
may be removed, subsequent to the reaction for which protection is employed,
without
disturbing the remainder of the molecule. Exemplary protecting groups include
ethers
(e.g., allyl, triphenylnnethyl (trityl or Tr), p-methoxybenzyl (PMB), p-
methoxphenyl
(PMP)), acetals (e.g., methoxymethyl (MOM), 6-methoxyethoxymethyl (MEM),
tetrahydropyranyl (THP), ethoxy ethyl (EE), methylthiomethyl (MTM), 2¨methoxy-
2-
propyl (MOP), 2-trimethylsilylethoxymethyl (SEM)), esters (e.g., benzoate
(Bz), allyl
carbonate, 2,2,2-trichloroethyl carbonate (Troc), 2-trimethylsilylethyl
carbonate), silyl
ethers (e.g., trimethylsilyl (TMS), triethylsilyl (TES), triisopropylsilyl
(TIPS), triphenylsilyl
(TPS), t-butyldimethylsilyl (TBDMS), t-butyldiphenylsilyl (TBDPS) and the
like. A variety
of protecting groups and the synthesis thereof may be found in "Greene's
Protective
Groups in Organic Synthesis," 4th Ed. by P.G.M. Wuts and T.W. Greene, John
Wiley &
Sons, Inc., 2007. Additionally, ¨0-Pro is equivalent to OPro.
[0077] The term "substituted hydrocarbyl" used herein refers to
hydrocarbyl moieties which are substituted with at least one atom other than
carbon,
including moieties in which a carbon chain atom is substituted with a
heteroatom such
18
WO 2015/066443 PCT/US2014/063372
as nitrogen, oxygen, silicon, phosphorous, boron, or a halogen atom, and
moieties in
which the carbon chain comprises additional substituents. These substituents
include
alkyl, alkoxy, acyl, acyloxy, alkenyl, alkenoxy, aryl, aryloxy, amino, amido,
acetal,
carbamyl, carbocyclo, cyano, ester, ether, halogen, heterocyclo, hydroxy,
keto, ketal,
phospho, nitro, and thio.
Examples
[0078] The following examples are included to demonstrate preferred
embodiments of the invention. It should be appreciated by those of skill in
the art that
the techniques disclosed in the examples represent techniques discovered by
the
inventors to function well in the practice of the invention. Those of skill in
the art should,
however, in light of the present disclosure, appreciate that many changes can
be made
in the specific embodiments that are disclosed and still obtain a like or
similar result
without departing from the spirit and scope of the invention, therefore all
matter set forth
is to be interpreted as illustrative and not in a limiting sense.
Example 1: One pot synthesis of nalbuphine from noroxymorphone
[0079] Noroxymorphone (20.00 g) and cyclobutanecarboxaldehyde (6.40
g) were stirred in DMF (40 g) for 30 min. A solution of 50% of sodium
triacetoxyborohydride in DMF (32 g) was added to the above reactor over a
period of 30
min, followed by addition of acetic acid (27.3 g) to form a clear solution. It
was stirred at
room temperature (20 C) for 2 hr and then at 60 C for another 1 hr after
additional 50%
of sodium triacetoxyborohydride in DMF (48 g) was added. Water (120 g) and
then c-
NRIOH (60 g) were added. The suspension formed was heated at 60 C for 1 hr,
cooled
down to 45 C, adjusted pH to 9.2 with c-NH4OH (¨ 20 g), and continued to cool
down to
rt (20 C) for 1 hr and filtered. The wet cake collected on a filter was washed
with water
(60 mL) and dried at 65 C for 18 hr to give 23.76 g of nalbuphine base as
white solids.
19
CA 2926726 2019-02-07
WO 2015/066443 PCMS2014/063372
The molar yield was 95.5% (equal to 118.8% wt/wt yield) and 6-a-OH : 6-3-OH
ratio
was 98.9 : 0.10.
Example 2: One pot synthesis of 6-a-naltrexol from noroxymorphone
[0080] Noroxymorphone (20.00 g) and cyclopropanecarboxaldehyde
(5.40
g) were stirred in DMF (40 g) for 60 min. A solution of 50% of sodium
triacetoxyborohydride in DMF (35 g) was added to the above reactor over a
period of 2
hr, followed by addition of acetic acid (27.3 g) to form a clear solution. It
was stirred at
room temperature (20 C) for 2 hr and then at 60 C for another 1 hr after
additional 50%
of sodium triacetoxyborohydride in DMF (45 g) was added. Water (120 g) and
then c-
NH4OH (60 g) were added. The suspension formed was heated at 60 C for 1 hr,
cooled
down to 45 C, adjusted pH to 9.2 with c-NH4OH (¨ 20 g), and continued to cool
down to
rt (20 C) for 1 hr and filtered. The wet cake collected on a filter was washed
with water
(60 mL) and dried at 65 C for 18 hr to give 18.71 g of 6-a--naltrexol base as
white
solids. The molar yield was 78% (equal to 93.6% wt/wt yield) and 6-a-OH : 6-6-
OH ratio
was 98.74 : 0.07.
Example 3: Conversion of noroxymorphone to nalbuphone
[0081] Noroxymorphone (20.00 g) and cyclobutanecarboxaldehyde (1.60
g) were stirred in DMF (10 g) for 30 min. A solution of 40% of sodium
triacetoxyborohydride in DMF (11.5 g) was added to the above reactor over a
period of
15 min. HPLC analysis indicated that there was 97.0% of product formed in the
solution.
Example 4: Conversion of noroxymorphone to naltrexone
[0082] Noroxymorphone (20.00 g) and cyclopropanecarboxaldehyde (5.40
g) were stirred in DMF (40 g) for 60 min. A solution of 50% of sodium
triacetoxyborohydride in DMF (35 g) was added to the above reactor over a
period of 2
hr. HPLC analysis indicated that there was 90% of product formed in the
solution.
CA 2926726 2019-02-07
